## Docket No.: CCI-069US

## **AMENDMENTS TO THE CLAIMS**

## **Listing of Claims**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

- 1. (Currently Amended) An isolated DH-PH tandem domain nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of
  - (a) the nucleotide sequence of SEQ ID NO:1; derived from the Ect 2 sequence and having the sequence as set out in DNA sequence 1 (SEQ ID NO:1).
  - (b) a nucleotide sequence of at least 70% identity to the entire nucleotide sequence of SEQ ID NO:1;
  - (c) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:3;
  - (d) a nucleotide sequence encoding an amino acid sequence of at least 80% identity to the entire amino acid sequence of SEQ ID NO:3; and
  - (e) a nucleotide sequence encoding a fragment of at least 5 contiguous amino acids of the amino acid sequence of SEQ ID NO:3.
- 2. (Currently Amended) [[An]]<u>The</u> isolated <u>nucleic acid molecule domain as claimed in of</u> claim 1 having a specificity for PtdIns3P, PtdIns5P or PtdIns3,5P<sub>2</sub>.
- 3. (Currently Amended) A method of screening for agents that modulate the interaction of [[the]]an Ect 2 [[PH]] Pleckstrin homology domain with a [[PIs]]phosphoinosite, comprising incubating a polypeptide comprising the Ect 2 [[PH]] Pleckstrin homology domain polypeptide and said [[PI]] phosphoinosite with a candidate agent under conditions conducive for binding and determining whether said candidate agent modulates the binding of the Ect 2 [[PH]] Pleckstrin homology domain with the [[PI]] phosphoinosite.
- 4. (Currently Amended) [[A]]The method as claimed in of claim 3 wherein the [[PI]] phosphoinosite is a PI having has a phosphate group at the 3 and/or 5 position.
- 5. (Currently Amended) [[A]]The method as claimed in of claim[[s]] 3 [[or 4]] wherein said agent is an antibody, a small organic molecule or a nucleic acid molecule.

Application No.: NEW APPLICATION Docket No.: CCI-069US

6. (Currently Amended) [[A]] The method as claimed in any of claim[[s]] 3 [[to 5]] wherein the [[PH]] Pleckstrin homology domain is provided as part of the construct having a sequence as set out in DNA sequence 1 (SEQ ID NO:1).encoded by a nucleic acid molecule selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:1;
- (b) a nucleotide sequence of at least 70% identity to the entire nucleotide sequence of SEQ ID NO:1;
- (c) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:3;
- (d) a nucleotide sequence encoding an amino acid sequence of at least 80% identity to the entire amino acid sequence of SEQ ID NO:3; and
- (e) a nucleotide sequence encoding a fragment of at least 5 contiguous amino acids of the amino acid sequence of SEQ ID NO:3.
- 7. (Currently Amended) A method of identifying an agent that modulates the cell cycle activity of Ect 2, the method comprising:
  - (a) providing a sample containing comprising a polypeptide comprising an Ect 2 [[PH]] Pleckstrin homology domain, and a candidate agent;
  - (b) measuring the binding of the polypeptide comprising [[an]]the Ect 2 [[PH]]

    Pleckstrin homology domain to the candidate agent in the sample; and
  - (c) comparing the binding of the polypeptide comprising [[an]]the Ect 2 [[PH]]

    Pleckstrin homology domain to the candidate agent in the sample with the binding of the polypeptide comprising [[an]]the Ect 2 [[PH]] Pleckstrin homology domain to a control agent, wherein the control agent is known to not bind to the polypeptide comprising an Ect 2 PH domain;

wherein an increase in the binding of the polypeptide comprising [[an]]the Ect 2 [[PH]] Pleckstrin homology domain to the candidate agent in the sample relative to the binding of the polypeptide comprising [[an]]the Ect 2 [[PH]] Pleckstrin homology domain to the control agent indicates that the candidate agent modulates the cell cycle function of Ect 2.

Application No.: NEW APPLICATION Docket No.: CCI-069US

8. (Currently Amended) The use of a polypeptide capable of binding to PIs having a 3 and/or 5 phosphate group but not capable of binding to a PI having a 4 phosphate group in a screening A method for identifying a compound suitable for that modulates[[ing]] signalling by a [[PI]] phosphoinosite having a 3 and/or 5 phosphate group comprising contacting a polypeptide which binds to the phosphoinosite but which does not bind to a phosphoinosite having a 4 phosphate group with the phosphoinosite and a candidate agent under conditions conducive for binding and determining the ability of the polypeptide to modulate signalling by the phosphoinosite.

- 9. (Currently Amended) A use as claimed in The method of claim 8 wherein the polypeptide comprises an Ect 2 [[PH]] Pleckstrin homology domain.
- 10. (New) The method of claim 4 wherein said agent is an antibody, a small organic molecule or a nucleic acid molecule.
- 11. (New) The method of claim 3, wherein the polypeptide comprising the Ect 2 Pleckstrin homology domain comprises an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEQ ID NO:3;
  - (b) an amino acid sequence of at least 80% identity to the entire amino acid sequence of SEQ ID NO:3;
  - (c) an amino acid sequence encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1;
  - (d) an amino acid sequence encoded by a nucleic acid molecule comprising a nucleotide sequence of at least 70% identity to the entire nucleotide sequence of SEQ ID NO:1;
  - (e) an amino acid sequence of at least 5 contiguous amino acids of the amino acid sequence of SEQ ID NO:2.
- 12. (New) The method of claim 7, wherein the polypeptide comprising the Ect 2 Pleckstrin homology domain comprises an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEQ ID NO:3;
  - (b) an amino acid sequence of at least 80% identity to the entire amino acid sequence of SEQ ID NO:3;

Application No.: NEW APPLICATION Docket No.: CCI-069US

(c) an amino acid sequence encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1;

- (d) an amino acid sequence encoded by a nucleic acid molecule comprising a nucleotide sequence of at least 70% identity to the entire nucleotide sequence of SEQ ID NO:1;
- (e) an amino acid sequence of at least 5 contiguous amino acids of the amino amino acid sequence of SEQ ID NO:2.
- 13. (New) The method of claim 9, wherein the polypeptide comprising the Ect 2 Pleckstrin homology domain comprises an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEQ ID NO:3;
  - (b) an amino acid sequence of at least 80% identity to the entire amino acid sequence of SEQ ID NO:3;
  - (c) an amino acid sequence encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1;
  - (d) an amino acid sequence encoded by a nucleic acid molecule comprising a nucleotide sequence of at least 70% identity to the entire nucleotide sequence of SEQ ID NO:1;
  - (e) an amino acid sequence of at least 5 contiguous amino acids of the amino amino acid sequence of SEQ ID NO:2.
- 14. (New) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of
  - (a) the amino acid sequence of SEQ ID NO:3;
  - (b) an amino acid sequence of at least 80% identity to the entire amino acid sequence of SEQ ID NO:3;
  - (c) an amino acid sequence encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1;
  - (d) an amino acid sequence encoded by a nucleic acid molecule comprising a nucleotide sequence of at least 70% identity to the entire nucleotide sequence of SEQ ID NO:1;
  - (e) an amino acid sequence of at least 5 contiguous amino acids of the amino amino acid sequence of SEQ ID NO:2.